Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
information for practice,
The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment…